# Efficacy and Safety Assessment of a Treatment Combining Rituximab and Belimumab in Adults With Persistent Immune Thrombocytopenia

> **NCT03154385** · NA · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 15 (actual)

## Conditions studied

- Immune Thrombocytopenia

## Interventions

- **DRUG:** Rituximab (Mabthera ®) Belimumab (Benlysta ®)

## Key facts

- **NCT ID:** NCT03154385
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-13
- **Primary completion:** 2019-11-13
- **Final completion:** 2019-11-13
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2020-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03154385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03154385, "Efficacy and Safety Assessment of a Treatment Combining Rituximab and Belimumab in Adults With Persistent Immune Thrombocytopenia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03154385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*